Alexza Pharmaceuticals Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2023-09-27: Study NCT05979415; Company role Lead sponsor; Phase Phase 2; Status Terminated.
- 2021-02-05: Study NCT04645953; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2020-03-10: Study NCT04327765; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2019-10-16: Study NCT04157933; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2023-09-27 | NCT05979415 Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes | Lead sponsor | Phase 2 | Terminated | Parkinson Disease | 8 | 2024-02-28 |
| 2021-02-05 | NCT04645953 Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome | Lead sponsor | Phase 2 | Completed Results posted | Cyclic Vomiting Syndrome | 150 | 2022-07-26 |
| 2020-03-10 | NCT04327765 Staccato® Granisetron Multiple Dose PK | Lead sponsor | Phase 1 | Completed | Healthy | 30 | 2020-08-15 |
| 2019-10-16 | NCT04157933 Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease | Lead sponsor | Phase 1 | Completed | Parkinson's Disease | 35 | 2020-03-06 |
| 2018-11-26 | NCT03822364 Staccato Apomorphine Single and Multi Dose PK | Lead sponsor | Phase 1 | Completed | Parkinson Disease | 56 | 2019-03-26 |
| 2014-11-04 | NCT03513549 Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder | Lead sponsor | Observational | Suspended | Agitation,Psychomotor | 10,000 | 2027-09 |
| 2013-06 | NCT01877642 ADASUVE-Lorazepam Drug-Drug Interaction | Lead sponsor | Phase 4 | Completed Results posted | Healthy Volunteers | 22 | 2013-07 |
| 2013-05 | NCT01854710 ADASUVE 2-dose Thorough QT/QTc Study | Lead sponsor | Phase 4 | Completed Results posted | Healthy Volunteers | 60 | 2013-07 |
| 2009-06 | NCT00889837 Staccato Loxapine Pulmonary Safety in Patients With COPD | Lead sponsor | Phase 1 | Completed | Chronic Obstructive Pulmonary Disease | 53 | 2009-08 |
| 2009-05 | NCT00890175 Staccato Loxapine Pulmonary Safety in Patients With Asthma | Lead sponsor | Phase 1 | Completed | Asthma | 52 | 2009-08 |
| 2009-04 | NCT00873769 Staccato Loxapine PK in Smokers and Nonsmokers | Lead sponsor | Phase 1 | Completed | Smoking, Cigarette | 35 | 2009-06 |
| 2009-01 | NCT00825500 Staccato Loxapine in Migraine (Out Patient) | Lead sponsor | Phase 2 | Completed Results posted | Migraine Headache | 366 | 2009-08 |
| 2008-11 | NCT00789360 Staccato Loxapine Pulmonary Safety in Healthy Volunteers | Lead sponsor | Phase 1 | Completed Results posted | Healthy | 30 | 2009-04 |
| 2008-07 | NCT00721955 Staccato Loxapine in Agitated Patients With Bipolar Disorder | Lead sponsor | Phase 3 | Completed Results posted | Bipolar I Disorder | 314 | 2008-10 |
| 2008-02 | NCT00628589 Staccato Loxapine in Agitated Patients With Schizophrenia | Lead sponsor | Phase 3 | Completed Results posted | Patients With Schizophrenia and Acute Agitation | 344 | 2008-05 |
| 2008-02 | NCT00620620 Staccato Zaleplon Single Dose Pharmacokinetics | Lead sponsor | Phase 1 | Completed | Healthy | 40 | 2008-03 |
| 2007-10 | NCT00555412 Staccato Loxapine Multidose PK | Lead sponsor | Phase 1 | Completed | Volunteers on Chronic, Stable Antipsychotic Regimens | 40 | 2007-12 |
| 2007-10 | NCT00543062 Staccato Prochlorperazine Thorough QT/QTc | Lead sponsor | Phase 1 | Completed Results posted | Cardiotoxicity | 48 | 2007-12 |
| 2007-06 | NCT00489476 Staccato Loxapine in Migraine (in Clinic) | Lead sponsor | Phase 2 | Completed Results posted | Migraine | 168 | 2007-12 |
| 2007-05 | NCT00477451 Staccato Alprazolam in Panic Attack | Lead sponsor | Phase 2 | Completed Results posted | Treatment of Induced Panic Attack | 49 | 2008-04 |
| 2006-08 | NCT00369577 Staccato Loxapine in Agitation (Proof of Concept) | Lead sponsor | Phase 2 | Completed Results posted | Schizophrenia | 129 | 2007-01 |
| 2006-04 | NCT00422812 Staccato Prochlorperazine in Migraine (Out Patient) | Lead sponsor | Phase 2 | Completed Results posted | Migraine Headache; Aura | 400 | 2007-01 |
| 2006-04 | NCT00402350 Staccato Fentanyl Single and Multidose PK | Lead sponsor | Phase 1 | Completed | Breakthrough Pain | 51 | 2006-11 |
| 2005-09 | NCT00444028 Staccato Loxapine Single Dose PK | Lead sponsor | Phase 1 | Completed Results posted | Schizophrenia | 50 | 2005-11 |
| 2005-06 | NCT00444522 Staccato Alprazolam Single Dose PK | Lead sponsor | Phase 1 | Completed | Healthy | 50 | 2005-08 |
| 2005-03 | NCT00610428 Staccato Prochlorperazine in Migraine (in Clinic) | Lead sponsor | Phase 2 | Completed Results posted | Migraine Headache, With or Without Aura | 75 | 2005-10 |